Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C

Detalhes bibliográficos
Autor(a) principal: Rodrigues,João Paulo Vilela
Data de Publicação: 2020
Outros Autores: Cazarim,Maurílio de Souza, Chachá,Silvana Gama Florencio, Martinelli,Ana de Lourdes Candolo, Pereira,Leonardo Régis Leira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Cadernos de Saúde Pública
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2020000205006
Resumo: Abstract: Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporation of PIs generated a significant financial impact. The aim of this study was to discuss the relevance of cost-effectiveness analysis through a study that involved the inclusion of PIs in a clinical protocol. The analysis was part of a real-life study that included patients infected with hepatitis C virus genotype 1 treated in a tertiary university hospital in Brazil. Triple therapies (TT) with ribavirin (RBV), peginterferon α-2a (Peg-INF α-2a) and BOC or TVR were compared to dual therapy with RBV and Peg-INF α-2a. Sensitivity analysis of the cost-effectiveness ratio indicated an 88.2% chance of TTs presenting a higher cost per cure. The incremental cost-effectiveness ratios (ICER) exceeded the Brazilian gross domestic product (GDP) per capita by three times in all proposed scenarios. The sensitivity of ICER showed an 88.4% chance of TT not being cost-effective. The impact of PI incorporation was negative and the conduct about this could have been different if a previous cost-effectiveness analysis had been conducted.
id FIOCRUZ-5_f7611aa6a31089618bb63da77a0f8cb1
oai_identifier_str oai:scielo:S0102-311X2020000205006
network_acronym_str FIOCRUZ-5
network_name_str Cadernos de Saúde Pública
repository_id_str
spelling Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis CEconomicsPharmaceuticalsDecision MakingHepatitis CProtease InhibitorsAbstract: Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporation of PIs generated a significant financial impact. The aim of this study was to discuss the relevance of cost-effectiveness analysis through a study that involved the inclusion of PIs in a clinical protocol. The analysis was part of a real-life study that included patients infected with hepatitis C virus genotype 1 treated in a tertiary university hospital in Brazil. Triple therapies (TT) with ribavirin (RBV), peginterferon α-2a (Peg-INF α-2a) and BOC or TVR were compared to dual therapy with RBV and Peg-INF α-2a. Sensitivity analysis of the cost-effectiveness ratio indicated an 88.2% chance of TTs presenting a higher cost per cure. The incremental cost-effectiveness ratios (ICER) exceeded the Brazilian gross domestic product (GDP) per capita by three times in all proposed scenarios. The sensitivity of ICER showed an 88.4% chance of TT not being cost-effective. The impact of PI incorporation was negative and the conduct about this could have been different if a previous cost-effectiveness analysis had been conducted.Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz2020-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2020000205006Cadernos de Saúde Pública v.36 n.2 2020reponame:Cadernos de Saúde Públicainstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZ10.1590/0102-311x00036619info:eu-repo/semantics/openAccessRodrigues,João Paulo VilelaCazarim,Maurílio de SouzaChachá,Silvana Gama FlorencioMartinelli,Ana de Lourdes CandoloPereira,Leonardo Régis Leiraeng2020-05-15T00:00:00Zoai:scielo:S0102-311X2020000205006Revistahttp://cadernos.ensp.fiocruz.br/csp/https://old.scielo.br/oai/scielo-oai.phpcadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br1678-44640102-311Xopendoar:2020-05-15T00:00Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
title Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
spellingShingle Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
Rodrigues,João Paulo Vilela
Economics
Pharmaceuticals
Decision Making
Hepatitis C
Protease Inhibitors
title_short Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
title_full Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
title_fullStr Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
title_full_unstemmed Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
title_sort Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
author Rodrigues,João Paulo Vilela
author_facet Rodrigues,João Paulo Vilela
Cazarim,Maurílio de Souza
Chachá,Silvana Gama Florencio
Martinelli,Ana de Lourdes Candolo
Pereira,Leonardo Régis Leira
author_role author
author2 Cazarim,Maurílio de Souza
Chachá,Silvana Gama Florencio
Martinelli,Ana de Lourdes Candolo
Pereira,Leonardo Régis Leira
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Rodrigues,João Paulo Vilela
Cazarim,Maurílio de Souza
Chachá,Silvana Gama Florencio
Martinelli,Ana de Lourdes Candolo
Pereira,Leonardo Régis Leira
dc.subject.por.fl_str_mv Economics
Pharmaceuticals
Decision Making
Hepatitis C
Protease Inhibitors
topic Economics
Pharmaceuticals
Decision Making
Hepatitis C
Protease Inhibitors
description Abstract: Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporation of PIs generated a significant financial impact. The aim of this study was to discuss the relevance of cost-effectiveness analysis through a study that involved the inclusion of PIs in a clinical protocol. The analysis was part of a real-life study that included patients infected with hepatitis C virus genotype 1 treated in a tertiary university hospital in Brazil. Triple therapies (TT) with ribavirin (RBV), peginterferon α-2a (Peg-INF α-2a) and BOC or TVR were compared to dual therapy with RBV and Peg-INF α-2a. Sensitivity analysis of the cost-effectiveness ratio indicated an 88.2% chance of TTs presenting a higher cost per cure. The incremental cost-effectiveness ratios (ICER) exceeded the Brazilian gross domestic product (GDP) per capita by three times in all proposed scenarios. The sensitivity of ICER showed an 88.4% chance of TT not being cost-effective. The impact of PI incorporation was negative and the conduct about this could have been different if a previous cost-effectiveness analysis had been conducted.
publishDate 2020
dc.date.none.fl_str_mv 2020-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2020000205006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2020000205006
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0102-311x00036619
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz
publisher.none.fl_str_mv Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz
dc.source.none.fl_str_mv Cadernos de Saúde Pública v.36 n.2 2020
reponame:Cadernos de Saúde Pública
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Cadernos de Saúde Pública
collection Cadernos de Saúde Pública
repository.name.fl_str_mv Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv cadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br
_version_ 1754115740698411008